PTIX | Protagenic Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.4004 - 0.4312
52 Week Range	0.4004 - 1.8700
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	94,054
Average Volume	292,561
Shares Outstanding	7,241,440
Market Cap	2,903,817
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-04-27

Valuation
Profitability
Growth
Health
P/E Ratio	-0.32
Forward P/E Ratio	N/A
EPS	-1.27
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	1
Country	USA
Website	PTIX

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.

PTIX's peers: BCDA, SBHMY, ZIVO, CYT, ELDN, RZLT, XOMAO, TPST, AVTE, ADAG, ACRV, ANTX, CYCC, FBIOP, ICCC, MRKR, NLSP, SVRA, XCUR, LSTA, LIPO, TOVX

*Chart delayed

Analyzing fundamentals for PTIX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see PTIX Fundamentals page.

Watching at PTIX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on PTIX Technicals page.